안과 검사용 체어 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 부문별, 최종 용도별, 지역별, 부문별 예측(2023-2030년)

Ophthalmic Examination Chairs Market Growth & Trends

The global ophthalmic examination chairs market size is expected to reach USD 139.67 million by 2030, based on a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 5.91% from 2023 to 2030. The growth is attributed to the increasing prevalence of eye-related diseases.

Growing cases of pediatric eye diseases lead to a surge in eye exams performed in hospitals, which is expected to increase demand for ophthalmic examination chairs. Pediatric eye disorders are more likely to affect children who have certain medical diseases, such as Down syndrome, preterm, juvenile idiopathic arthritis, neurofibromatosis, or who have a family record of amblyopia, retinoblastoma, strabismus, congenital cataracts, or glaucoma.

In addition, many government and non-government organizations are investing in and implementing programs to raise awareness about adopting eye screening practices. In developing nations like India, the government sponsors schools to enroll students in eye screening programs and offers free ocular surgery if necessary to raise awareness among people.

For instance, the chief minister of Goa, India, claimed in January 2023 that the state had offered free ophthalmic examinations to more than 2 lakh students in Goa. The government is also taking steps to offer essential medical services, such as free eye procedures. As a result, more eye screenings will be conducted around the country, increasing the demand for ophthalmic examination chairs.

Ophthalmic Examination Chairs Market Report Highlights

• Based on technology, the electric segment accounted for the largest market share of 28.11% in 2022, as such chairs develop a comfortable environment for the patient, are simple to convert to the supine position, and give a single platform for use before and after surgery
• Based on section, the 3-section segment dominated the market with a share of 41.34% in 2022, due to the availability of various features and adjustments in 3-section chairs
• Based on end-use, the hospital's segment dominated the market with a share of 33.5% in 2022, owing to the increase in eye infections, which has led to increased hospital visits
• North America dominated the global ophthalmic examination chairs industry with a share of 44.49% in 2022, owing to well-established healthcare infrastructure and the rising prevalence of vision-related disorders

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Technology
  • 1.1.2. Section
  • 1.1.3. End-use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Details of primary research
    • 1.3.4.1. Data for primary interviews in North America
    • 1.3.4.2. Data for primary interviews in Europe
    • 1.3.4.3. Data for primary interviews in Asia Pacific
    • 1.3.4.4. Data for primary interviews in Latin America
    • 1.3.4.5. Data for Primary Interviews in MEA
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Technology outlook
  • 2.2.2. Section outlook
  • 2.2.3. End-use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Ophthalmic Examination Chairs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Industry Value Chain Analysis
  • 3.3.1. Reimbursement framework
• 3.4. Market Dynamics
  • 3.4.1. Market driver analysis
    • 3.4.1.1. Growing prevalence of eye disorders
    • 3.4.1.2. Technological advancements
    • 3.4.1.3. Rising geriatric population with vision-related diseases
  • 3.4.2. Market restraint analysis
    • 3.4.2.1. Lack of awareness about eye infections in developing countries
    • 3.4.2.2. Lack of adoption of advanced ophthalmic examination chairs
• 3.5. Ophthalmic Examination Chairs Market Analysis Tools
  • 3.5.1. Industry Analysis - Porter's
    • 3.5.1.1. Supplier power
    • 3.5.1.2. Buyer power
    • 3.5.1.3. Substitution threat
    • 3.5.1.4. Threat of new entrant
    • 3.5.1.5. Competitive rivalry
  • 3.5.2. PESTEL Analysis
    • 3.5.2.1. Political landscape
    • 3.5.2.2. Technological landscape
    • 3.5.2.3. Economic landscape
  • 3.5.3. Major Deals & Strategic Alliances Analysis
  • 3.5.4. Market Entry Strategies

Chapter 4. Ophthalmic Examination Chairs Market: Technology Estimates & Trend Analysis

• 4.1. Definitions and Scope
  • 4.1.1. Electric
  • 4.1.2. Mechanical
  • 4.1.3. Hydraulic
  • 4.1.4. Pneumatic
  • 4.1.5. Others
• 4.2. Technology Market Share, 2022 & 2030
• 4.3. Segment Dashboard
• 4.4. Global Ophthalmic Examination Chairs Market by Technology Outlook
• 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5.1. Electric
    • 4.5.1.1. Electric market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.2. Mechanical
    • 4.5.2.1. Mechanical market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.3. Hydraulic
    • 4.5.3.1. Hydraulic market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.4. Pneumatic
    • 4.5.4.1. Pneumatic market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Other market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Ophthalmic Examination Chairs Market: Section Estimates & Trend Analysis

• 5.1. Definitions and Scope
  • 5.1.1. 2-section
  • 5.1.2. 3-section
  • 5.1.3. 4-section
• 5.2. Section Market Share, 2022 & 2030
• 5.3. Segment Dashboard
• 5.4. Ophthalmic Examination Chairs Market by Section Outlook
• 5.5. Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the following
  • 5.5.1. 2-section
    • 5.5.1.1. 2-section market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5.2. 3-section
    • 5.5.2.1. 3-section market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5.3. 4-section
    • 5.5.3.1. 4-section market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Ophthalmic Examination Chairs Market: End-use Estimates & Trend Analysis

• 6.1. Definitions and Scope
  • 6.1.1. Hospitals
  • 6.1.2. Ambulatory Surgical Centers
  • 6.1.3. Specialty Clinics
  • 6.1.4. Others
• 6.2. End-use Market Share, 2022 & 2030
• 6.3. Segment Dashboard
• 6.4. Ophthalmic Examination Chairs Market by End-use Outlook
• 6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5.1. Hospitals
    • 6.5.1.1. Hospitals market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.2. Ambulatory Surgical Centers
    • 6.5.2.1. Ambulatory Surgical Centers market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.3. Specialty Clinics
    • 6.5.3.1. Specialty Clinics market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.4. Others
    • 6.5.4.1. Others market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Ophthalmic Examination Chairs Market: Regional Estimates & Trend Analysis

• 7.1. Regional market share analysis, 2022 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Regional Market Share and Leading Players, 2022
  • 7.4.1. North America
  • 7.4.2. Europe
  • 7.4.3. Asia Pacific
  • 7.4.4. Latin America
  • 7.4.5. Middle East and Africa
• 7.5. Market Application, & Forecasts and Trend Analysis, 2018 to 2030:
• 7.6. North America
  • 7.6.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 7.6.2. U.S.
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. U.S. market estimates and forecasts, 2018 - 2030
  • 7.6.3. Canada
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Canada market estimates and forecasts, 2018 - 2030
• 7.7. Europe
  • 7.7.1. UK
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Competitive Scenario
    • 7.7.1.3. Regulatory framework
    • 7.7.1.4. Reimbursement scenario
    • 7.7.1.5. UK market estimates and forecasts, 2018 - 2030
  • 7.7.2. Germany
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Germany market estimates and forecasts, 2018 - 2030
  • 7.7.3. France
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. France market estimates and forecasts, 2018 - 2030
  • 7.7.4. Italy
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. Italy market estimates and forecasts, 2018 - 2030
  • 7.7.5. Spain
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. Spain market estimates and forecasts, 2018 - 2030
  • 7.7.6. Denmark
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory framework
    • 7.7.6.4. Reimbursement scenario
    • 7.7.6.5. Denmark market estimates and forecasts, 2018 - 2030
  • 7.7.7. Sweden
    • 7.7.7.1. Key country dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory framework
    • 7.7.7.4. Reimbursement scenario
    • 7.7.7.5. Sweden market estimates and forecasts, 2018 - 2030
  • 7.7.8. Norway
    • 7.7.8.1. Key country dynamics
    • 7.7.8.2. Competitive Scenario
    • 7.7.8.3. Regulatory framework
    • 7.7.8.4. Reimbursement scenario
    • 7.7.8.5. Norway market estimates and forecasts, 2018 - 2030
• 7.8. Asia Pacific
  • 7.8.1. Japan
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Competitive Scenario
    • 7.8.1.3. Regulatory framework
    • 7.8.1.4. Reimbursement scenario
    • 7.8.1.5. Japan market estimates and forecasts, 2018 - 2030
  • 7.8.2. India
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. India market estimates and forecasts, 2018 - 2030
  • 7.8.3. China
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. China market estimates and forecasts, 2018 - 2030
  • 7.8.4. South Korea
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory framework
    • 7.8.4.4. Reimbursement scenario
    • 7.8.4.5. South Korea market estimates and forecasts, 2018 - 2030
  • 7.8.5. Australia
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory framework
    • 7.8.5.4. Reimbursement scenario
    • 7.8.5.5. Australia market estimates and forecasts, 2018 - 2030
  • 7.8.6. Thailand
    • 7.8.6.1. Key country dynamics
    • 7.8.6.2. Competitive Scenario
    • 7.8.6.3. Regulatory framework
    • 7.8.6.4. Reimbursement scenario
    • 7.8.6.5. Thailand market estimates and forecasts, 2018 - 2030
• 7.9. Latin America
  • 7.9.1. Brazil
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Competitive Scenario
    • 7.9.1.3. Regulatory framework
    • 7.9.1.4. Reimbursement scenario
    • 7.9.1.5. Brazil market estimates and forecasts, 2018 - 2030
  • 7.9.2. Mexico
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Competitive Scenario
    • 7.9.2.3. Regulatory framework
    • 7.9.2.4. Reimbursement scenario
    • 7.9.2.5. Mexico market estimates and forecasts, 2018 - 2030
  • 7.9.3. Argentina
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Competitive Scenario
    • 7.9.3.3. Regulatory framework
    • 7.9.3.4. Reimbursement scenario
    • 7.9.3.5. Argentina market estimates and forecasts, 2018 - 2030
• 7.10. MEA
  • 7.10.1. South Africa
    • 7.10.1.1. Key country dynamics
    • 7.10.1.2. Competitive Scenario
    • 7.10.1.3. Regulatory framework
    • 7.10.1.4. Reimbursement scenario
    • 7.10.1.5. South Africa market estimates and forecasts, 2018 - 2030
  • 7.10.2. Saudi Arabia
    • 7.10.2.1. Key country dynamics
    • 7.10.2.2. Competitive Scenario
    • 7.10.2.3. Regulatory framework
    • 7.10.2.4. Reimbursement scenario
    • 7.10.2.5. Saudi Arabia market estimates and forecasts, 2018 - 2030
  • 7.10.3. UAE
    • 7.10.3.1. Key country dynamics
    • 7.10.3.2. Competitive Scenario
    • 7.10.3.3. Regulatory framework
    • 7.10.3.4. Reimbursement scenario
    • 7.10.3.5. UAE market estimates and forecasts, 2018 - 2030
  • 7.10.4. Kuwait
    • 7.10.4.1. Key country dynamics
    • 7.10.4.2. Competitive Scenario
    • 7.10.4.3. Regulatory framework
    • 7.10.4.4. Reimbursement scenario
    • 7.10.4.5. Kuwait market estimates and forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
  • 8.2.1. Innovators
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2022
  • 8.3.4. Topcon Corporation
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Coburn Technologies, Inc. ( SDC Technologies, Inc.)
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Haag-Streit USA
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Takagi Ophthalmic Instruments Europe Limited
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Mid Central Medical
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. AKRUS GmbH & Co. K.G.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Lemi MD (Brusaferri & C. srl.)
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Bon Optic Vertriebsges.mbH
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. BTC SRL
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Vermund Larsen A/S
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives